BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.7% on Disappointing Earnings

Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) fell 6.7% during mid-day trading on Wednesday following a weaker than expected earnings announcement. The company traded as low as $64.36 and last traded at $63.7250. 2,696,521 shares changed hands during trading, a decline of 18% from the average session volume of 3,279,146 shares. The stock had previously closed at $68.31.

The company reported ($1.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.25). The company had revenue of $154.18 million for the quarter, compared to analysts’ expectations of $150.71 million. The business’s quarterly revenue was up 2521.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.40) earnings per share.

Key BridgeBio Pharma News

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Several Wall Street analysts raised targets/ratings this morning (Morgan Stanley to $98, Truist to $95), signaling continued bullish institutional conviction that could support upside over time. Analyst raises
• Positive Sentiment: BridgeBio reported a meaningful revenue beat for Q4 with revenue of $154.18M and huge year‑over‑year growth (reported +2521% YoY), showing commercial traction that investors can point to as a growth signal. Revenue beat article
• Neutral Sentiment: Company issued its full Q4 and FY2025 results and provided commercial updates (Attruby progress highlighted) — useful for modeling future revenue but no new guidance that immediately changes near‑term outlook. Earnings release
• Neutral Sentiment: Transcripts and call coverage are available for deeper read‑throughs (investors should check the conference call for commercial metrics, margin commentary and product rollout cadence). Earnings transcript
• Negative Sentiment: EPS missed consensus: BridgeBio reported a loss of ($1.00) vs. the expected ($0.75), which is likely the main catalyst for the intraday weakness as it increases short‑term uncertainty about profitability and near‑term cash use. EPS miss
• Negative Sentiment: Insider selling: CEO Neil Kumar sold ~28,053 shares recently (part of a series of sales), which can create negative optics and short‑term pressure on the stock. Insider sale

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on BBIO. Morgan Stanley increased their target price on BridgeBio Pharma from $96.00 to $98.00 and gave the stock an “overweight” rating in a research note on Wednesday. Raymond James Financial set a $89.00 price objective on BridgeBio Pharma and gave the stock an “outperform” rating in a research report on Thursday, February 12th. HC Wainwright raised their price target on shares of BridgeBio Pharma from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, February 17th. Oppenheimer decreased their price objective on shares of BridgeBio Pharma from $83.00 to $81.00 and set an “outperform” rating for the company in a research report on Wednesday. Finally, Barclays assumed coverage on shares of BridgeBio Pharma in a research report on Wednesday, January 28th. They set an “overweight” rating on the stock. Twenty-two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus target price of $82.50.

Insider Activity at BridgeBio Pharma

In other BridgeBio Pharma news, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $74.40, for a total transaction of $2,976,000.00. Following the completion of the transaction, the chief executive officer owned 775,686 shares of the company’s stock, valued at approximately $57,711,038.40. This trade represents a 4.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Thomas Trimarchi sold 13,600 shares of the business’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $74.72, for a total transaction of $1,016,192.00. Following the completion of the transaction, the chief financial officer directly owned 336,585 shares in the company, valued at $25,149,631.20. This trade represents a 3.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 204,174 shares of company stock worth $15,012,335 over the last ninety days. Corporate insiders own 18.20% of the company’s stock.

Hedge Funds Weigh In On BridgeBio Pharma

Several institutional investors and hedge funds have recently bought and sold shares of the company. Corient Private Wealth LLC purchased a new position in shares of BridgeBio Pharma in the second quarter worth about $643,000. WINTON GROUP Ltd purchased a new stake in shares of BridgeBio Pharma in the second quarter valued at approximately $3,856,000. Principal Financial Group Inc. lifted its position in BridgeBio Pharma by 23.0% during the third quarter. Principal Financial Group Inc. now owns 1,267,412 shares of the company’s stock worth $65,829,000 after buying an additional 236,885 shares in the last quarter. Federated Hermes Inc. boosted its stake in BridgeBio Pharma by 53.0% during the third quarter. Federated Hermes Inc. now owns 424,695 shares of the company’s stock worth $22,059,000 after buying an additional 147,108 shares during the last quarter. Finally, L & S Advisors Inc acquired a new stake in shares of BridgeBio Pharma in the 3rd quarter worth $877,000. 99.85% of the stock is owned by hedge funds and other institutional investors.

BridgeBio Pharma Trading Down 6.3%

The firm has a fifty day moving average price of $75.24 and a 200 day moving average price of $64.53. The firm has a market cap of $12.34 billion, a PE ratio of -15.33 and a beta of 1.13.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.